- Telehealth Visits
- Insurance plan information
Robert E. Goldsby, MD
Medical Oncology • Pediatric Medical OncologyDirector, UCSF Survivors of Childhood Cancer Program- Telehealth Visits
- Insurance plan information
Robert E. Goldsby, MD
Medical Oncology • Pediatric Medical OncologyDirector, UCSF Survivors of Childhood Cancer Program- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Robert E. Goldsby is a pediatric cancer specialist at UCSF Benioff Children's Hospitals. He directs the UCSF Survivors of Childhood Cancer Program, which provides care and long-term follow-up for patients who had cancer in childhood. One of his particular areas of interest is treating young patients with high-risk sarcomas.
Goldsby earned his medical degree at the University of Vermont. He completed a residency in pediatrics at UCSF Benioff Children's Hospital Oakland, followed by a fellowship in pediatric hematology and oncology at Intermountain Primary Children's Hospital, an affiliate of the University of Utah School of Medicine.
Goldsby has received numerous awards and grants, including grants from the American Cancer Society and Hope Street Kids.
Education & training
Board certification
- Pediatric Hematology-Oncology, American Board of Pediatrics
- Pediatrics, American Board of Pediatrics
Degree
- MD, University of Vermont College of Medicine
My expertise
Specialties
- Medical Oncology
- Pediatric Medical Oncology
- Hematology
Conditions
Clinical Trials query: q=health_gateway_id_ss%3A%28%22876%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%22876%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Publication%22
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.